Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences (Nasdaq: ARTL) has approved a 1-for-9 reverse stock split of its common stock, with trading on a split-adjusted basis on the Nasdaq Capital Market expected to begin at market open on August 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artelo Biosciences (Nasdaq: ARTL) has approved a 1-for-9 reverse stock split of its common stock, with trading on a split-adjusted basis on the Nasdaq Capital Market expected to begin at market open on August 31, 2026. The Reverse Split is intended to increase the price per share to improve marketability and liquidity. Each nine issued and outstanding common shares will be automatically combined into one share, with no fractional shares issued; any fractional entitlement will be rounded up to one whole share. According to Artelo, shareholder pro-rata ownership will be unchanged, all outstanding warrants and other derivatives will adjust per their terms, and approximately 547,774 common shares will be outstanding immediately after effectiveness.
Positive
- Reverse stock split ratio 1-for-9, effective for trading August 31, 2026
- Post-split outstanding common shares expected to be about 547,774
- Company aims to improve share price, marketability, and liquidity via reverse split
Negative
- None.
News Explained
The announced 1-for-9 reverse split will reduce the number of shares and proportionally raise the per-share price, while the split itself does not change the company’s value; existing holders’ ownership percentages remain unchanged.
Details
Market move: ARTL -6.98% in the Aug 27 session. 1-for-9 reverse stock split
On Aug 27, the day this news came out, ARTL closed 6.98% below the previous close. Argus tracked a peak move of +40.1% during that session. Our momentum scanner recorded 5 alerts for this stock that day. Relative volume reached 9.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 27 session.
Key Figures
- Reverse split ratio
- 1-for-9
- Common stock reverse split
- Split-adjusted trading date
- August 31, 2026
- Nasdaq Capital Market market open
- New CUSIP
- 04301G805
- Common stock following the reverse split
- Shares outstanding
- 547,774 shares
- Immediately after the reverse split becomes effective
Previous Stock split Reports
-
3-for-1 reverse split announced to improve marketability and liquidity
-
6-for-1 reverse split announced with split-adjusted trading
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
cusip regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open on August 31, 2026. The Reverse Split is being effected in order to increase the price per share of the Common Stock to improve its marketability and liquidity. The new CUSIP number for the Common Stock following the Reverse Split will be 04301G805.
As a result of the Reverse Split, each nine shares of the Company’s issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares will be issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share will automatically be entitled to receive one whole share of Common Stock for each such fractional share. Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the Reverse Split and no further action is required by shareholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the Reverse Split. Immediately after the Reverse Split becomes effective, there will be approximately 547,774 shares of Common Stock issued and outstanding. For further details, all shareholders are invited to review the Current Report on Form 8-K regarding the Reverse Split which will be filed August 27, 2026.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.